---
layout: default
title: LLM-Based Support for Diabetes Diagnosis: Opportunities, Scenarios, and Challenges with GPT-5
---

# LLM-Based Support for Diabetes Diagnosis: Opportunities, Scenarios, and Challenges with GPT-5

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2509.21450" class="toolbar-btn" target="_blank">ğŸ“„ arXiv: 2509.21450v1</a>
  <a href="https://arxiv.org/pdf/2509.21450.pdf" class="toolbar-btn" target="_blank">ğŸ“¥ PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2509.21450v1" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2509.21450v1', 'LLM-Based Support for Diabetes Diagnosis: Opportunities, Scenarios, and Challenges with GPT-5')" title="æ·»åŠ åˆ°æ”¶è—å¤¹">â˜† æ”¶è—</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">ğŸ”— åˆ†äº«</button>
</div>


**ä½œè€…**: Gaurav Kumar Gupta, Nirajan Acharya, Pranal Pande

**åˆ†ç±»**: cs.CL

**å‘å¸ƒæ—¥æœŸ**: 2025-09-25

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**åˆ©ç”¨GPT-5è¾…åŠ©ç³–å°¿ç—…è¯Šæ–­ï¼Œæå‡ä¸´åºŠå†³ç­–æ”¯æŒä¸æ‚£è€…ç†è§£**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **æ”¯æŸ±ä¹ï¼šå…·èº«å¤§æ¨¡å‹ (Embodied Foundation Models)**

**å…³é”®è¯**: `ç³–å°¿ç—…è¯Šæ–­` `å¤§å‹è¯­è¨€æ¨¡å‹` `GPT-5` `ä¸´åºŠå†³ç­–æ”¯æŒ` `è¿œç¨‹å¥åº·ç›‘æµ‹`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. ç°æœ‰ç³–å°¿ç—…è¯Šæ–­é¢ä¸´æ—©æœŸè¯†åˆ«å›°éš¾ï¼Œç—‡çŠ¶æ¨¡ç³Šä¸”é•¿æœŸç›‘æµ‹éœ€æ±‚é«˜ï¼ŒäºŸéœ€è¾…åŠ©å†³ç­–å·¥å…·ã€‚
2. è®ºæ–‡åˆ©ç”¨GPT-5ï¼Œé€šè¿‡æ¨¡æ‹Ÿä¸´åºŠåœºæ™¯ï¼Œç”Ÿæˆç»“æ„åŒ–ã€å¯è§£é‡Šçš„è¯Šæ–­ç»“æœå’Œæ‚£è€…å‹å¥½çš„è§£é‡Šã€‚
3. å®éªŒè¡¨æ˜GPT-5ä¸ADAæ ‡å‡†é«˜åº¦ä¸€è‡´ï¼Œæœ‰æœ›æˆä¸ºä¸´åºŠåŒ»ç”Ÿå’Œæ‚£è€…çš„åŒé‡ç”¨é€”å·¥å…·ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ç³–å°¿ç—…æ˜¯ä¸€ç§ä¸»è¦çš„å…¨çƒå¥åº·æŒ‘æˆ˜ï¼Œå½±å“ç€å…¨çƒè¶…è¿‡5äº¿æˆå¹´äººï¼Œä¸”æ‚£ç—…ç‡é¢„è®¡å°†ç»§ç»­ä¸Šå‡ã€‚å°½ç®¡ç¾å›½ç³–å°¿ç—…åä¼š(ADA)æä¾›äº†æ˜ç¡®çš„è¯Šæ–­é˜ˆå€¼ï¼Œä½†ç”±äºç—‡çŠ¶æ¨¡ç³Šã€å®éªŒå®¤æ•°å€¼æ¥è¿‘ä¸´ç•Œå€¼ã€å¦Šå¨ å¤æ‚æ€§ä»¥åŠé•¿æœŸç›‘æµ‹çš„éœ€æ±‚ï¼Œæ—©æœŸè¯†åˆ«ä»ç„¶å›°éš¾ã€‚å¤§å‹è¯­è¨€æ¨¡å‹(LLM)çš„è¿›æ­¥ä¸ºé€šè¿‡ç»“æ„åŒ–ã€å¯è§£é‡Šå’Œå¯¹æ‚£è€…å‹å¥½çš„è¾“å‡ºæ¥å¢å¼ºå†³ç­–æ”¯æŒæä¾›äº†æœºä¼šã€‚æœ¬ç ”ç©¶ä½¿ç”¨å®Œå…¨åŸºäºåˆæˆç—…ä¾‹çš„æ¨¡æ‹Ÿæ¡†æ¶è¯„ä¼°äº†æœ€æ–°çš„ç”Ÿæˆå¼é¢„è®­ç»ƒTransformeræ¨¡å‹GPT-5ï¼Œè¿™äº›ç—…ä¾‹ä¸ADA 2025å¹´æŠ¤ç†æ ‡å‡†å¯¹é½ï¼Œå¹¶å—åˆ°åŒ…æ‹¬NHANESã€Pima Indiansã€EyePACSå’ŒMIMIC-IVç­‰å…¬å…±æ•°æ®é›†çš„å¯å‘ã€‚æµ‹è¯•äº†äº”ä¸ªä»£è¡¨æ€§åœºæ™¯ï¼šç—‡çŠ¶è¯†åˆ«ã€å®éªŒå®¤è§£é‡Šã€å¦Šå¨ ç³–å°¿ç—…ç­›æŸ¥ã€è¿œç¨‹ç›‘æµ‹å’Œå¤šæ¨¡æ€å¹¶å‘ç—‡æ£€æµ‹ã€‚å¯¹äºæ¯ä¸ªåœºæ™¯ï¼ŒGPT-5å¯¹ç—…ä¾‹è¿›è¡Œåˆ†ç±»ï¼Œç”Ÿæˆä¸´åºŠåŸç†ï¼Œäº§ç”Ÿæ‚£è€…è§£é‡Šï¼Œå¹¶è¾“å‡ºç»“æ„åŒ–çš„JSONæ‘˜è¦ã€‚ç»“æœè¡¨æ˜ï¼ŒGPT-5ä¸ADAå®šä¹‰çš„æ ‡å‡†é«˜åº¦ä¸€è‡´ï¼Œè¡¨æ˜GPT-5å¯ä»¥ä½œä¸ºä¸´åºŠåŒ»ç”Ÿå’Œæ‚£è€…çš„åŒé‡ç”¨é€”å·¥å…·ï¼ŒåŒæ—¶å¼ºè°ƒäº†å¯é‡å¤è¯„ä¼°æ¡†æ¶å¯¹äºè´Ÿè´£ä»»åœ°è¯„ä¼°åŒ»ç–—ä¿å¥é¢†åŸŸLLMçš„é‡è¦æ€§ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šç³–å°¿ç—…çš„æ—©æœŸè¯Šæ–­é¢ä¸´æŒ‘æˆ˜ï¼Œç°æœ‰æ–¹æ³•éš¾ä»¥æœ‰æ•ˆè¯†åˆ«æ¨¡ç³Šç—‡çŠ¶å’Œå¤„ç†å¤æ‚çš„ä¸´åºŠæ•°æ®ã€‚ä¸´åºŠåŒ»ç”Ÿéœ€è¦æ›´æœ‰æ•ˆçš„å†³ç­–æ”¯æŒå·¥å…·ï¼Œè€Œæ‚£è€…ä¹Ÿéœ€è¦æ˜“äºç†è§£çš„è¯Šæ–­è§£é‡Šã€‚ç°æœ‰æ–¹æ³•çš„ç—›ç‚¹åœ¨äºç¼ºä¹èƒ½å¤Ÿç»¼åˆå¤„ç†å¤šæ¨¡æ€æ•°æ®ã€æä¾›æ¸…æ™°è§£é‡Šå’Œæ”¯æŒè¿œç¨‹ç›‘æµ‹çš„æ™ºèƒ½ç³»ç»Ÿã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šæœ¬ç ”ç©¶çš„æ ¸å¿ƒæ€è·¯æ˜¯åˆ©ç”¨å¤§å‹è¯­è¨€æ¨¡å‹GPT-5çš„å¼ºå¤§è‡ªç„¶è¯­è¨€å¤„ç†èƒ½åŠ›ï¼Œæ„å»ºä¸€ä¸ªèƒ½å¤Ÿæ¨¡æ‹Ÿä¸´åºŠè¯Šæ–­è¿‡ç¨‹çš„æ™ºèƒ½ç³»ç»Ÿã€‚é€šè¿‡å°†ä¸´åºŠæ•°æ®è½¬åŒ–ä¸ºGPT-5å¯ä»¥ç†è§£çš„æ–‡æœ¬æ ¼å¼ï¼Œå¹¶åˆ©ç”¨å…¶ç”Ÿæˆèƒ½åŠ›ï¼Œå®ç°å¯¹ç³–å°¿ç—…ç—…ä¾‹çš„åˆ†ç±»ã€ä¸´åºŠåŸç†çš„ç”Ÿæˆå’Œæ‚£è€…è§£é‡Šçš„è¾“å‡ºã€‚è¿™æ ·è®¾è®¡çš„ç›®çš„æ˜¯ä¸ºäº†æä¾›æ›´å…¨é¢ã€å¯è§£é‡Šå’Œæ˜“äºç†è§£çš„è¯Šæ–­ä¿¡æ¯ï¼Œä»è€Œè¾…åŠ©ä¸´åºŠå†³ç­–å’Œæé«˜æ‚£è€…ä¾ä»æ€§ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šè¯¥ç ”ç©¶çš„æŠ€æœ¯æ¡†æ¶ä¸»è¦åŒ…æ‹¬ä»¥ä¸‹å‡ ä¸ªé˜¶æ®µï¼š1) æ•°æ®å‡†å¤‡ï¼šåŸºäºADAæ ‡å‡†å’Œå…¬å…±æ•°æ®é›†ï¼ˆå¦‚NHANESã€Pima Indiansã€EyePACSå’ŒMIMIC-IVï¼‰æ„å»ºåˆæˆç—…ä¾‹ï¼›2) åœºæ™¯è®¾è®¡ï¼šè®¾è®¡äº”ä¸ªä»£è¡¨æ€§ä¸´åºŠåœºæ™¯ï¼ŒåŒ…æ‹¬ç—‡çŠ¶è¯†åˆ«ã€å®éªŒå®¤è§£é‡Šã€å¦Šå¨ ç³–å°¿ç—…ç­›æŸ¥ã€è¿œç¨‹ç›‘æµ‹å’Œå¤šæ¨¡æ€å¹¶å‘ç—‡æ£€æµ‹ï¼›3) æ¨¡å‹åº”ç”¨ï¼šå°†ç—…ä¾‹æ•°æ®è¾“å…¥GPT-5ï¼Œè¦æ±‚å…¶è¿›è¡Œç—…ä¾‹åˆ†ç±»ã€ç”Ÿæˆä¸´åºŠåŸç†ã€äº§ç”Ÿæ‚£è€…è§£é‡Šå’Œè¾“å‡ºç»“æ„åŒ–çš„JSONæ‘˜è¦ï¼›4) ç»“æœè¯„ä¼°ï¼šè¯„ä¼°GPT-5çš„è¾“å‡ºç»“æœä¸ADAæ ‡å‡†çš„å¯¹é½ç¨‹åº¦ï¼Œå¹¶åˆ†æå…¶åœ¨ä¸åŒåœºæ™¯ä¸‹çš„è¡¨ç°ã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ¬ç ”ç©¶çš„å…³é”®åˆ›æ–°åœ¨äºå°†å¤§å‹è¯­è¨€æ¨¡å‹GPT-5åº”ç”¨äºç³–å°¿ç—…è¯Šæ–­é¢†åŸŸï¼Œå¹¶æ„å»ºäº†ä¸€ä¸ªå¯é‡å¤çš„è¯„ä¼°æ¡†æ¶ã€‚ä¸ç°æœ‰æ–¹æ³•ç›¸æ¯”ï¼Œè¯¥æ–¹æ³•èƒ½å¤Ÿç»¼åˆå¤„ç†å¤šæ¨¡æ€æ•°æ®ï¼Œç”Ÿæˆæ¸…æ™°çš„ä¸´åºŠåŸç†å’Œæ‚£è€…è§£é‡Šï¼Œå¹¶æ”¯æŒè¿œç¨‹ç›‘æµ‹ã€‚æ­¤å¤–ï¼Œè¯¥ç ”ç©¶å¼ºè°ƒäº†å¯é‡å¤è¯„ä¼°æ¡†æ¶çš„é‡è¦æ€§ï¼Œä¸ºè´Ÿè´£ä»»åœ°è¯„ä¼°åŒ»ç–—ä¿å¥é¢†åŸŸLLMæä¾›äº†å‚è€ƒã€‚

**å…³é”®è®¾è®¡**ï¼šç ”ç©¶ä¸­å…³é”®çš„è®¾è®¡åŒ…æ‹¬ï¼š1) åˆæˆç—…ä¾‹çš„æ„å»ºï¼Œç¡®ä¿ç—…ä¾‹æ•°æ®ä¸ADAæ ‡å‡†å¯¹é½ï¼›2) äº”ä¸ªä»£è¡¨æ€§ä¸´åºŠåœºæ™¯çš„è®¾è®¡ï¼Œè¦†ç›–äº†ç³–å°¿ç—…è¯Šæ–­çš„å„ä¸ªæ–¹é¢ï¼›3) GPT-5çš„æç¤ºå·¥ç¨‹ï¼Œç¡®ä¿å…¶èƒ½å¤Ÿç”Ÿæˆå‡†ç¡®ã€å¯è§£é‡Šå’Œæ‚£è€…å‹å¥½çš„è¾“å‡ºï¼›4) è¯„ä¼°æŒ‡æ ‡çš„é€‰æ‹©ï¼Œç”¨äºè¯„ä¼°GPT-5çš„è¾“å‡ºç»“æœä¸ADAæ ‡å‡†çš„å¯¹é½ç¨‹åº¦ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

å®éªŒç»“æœè¡¨æ˜ï¼ŒGPT-5åœ¨æ¨¡æ‹Ÿçš„ç³–å°¿ç—…è¯Šæ–­åœºæ™¯ä¸­è¡¨ç°å‡ºä¸ADAæ ‡å‡†çš„é«˜åº¦ä¸€è‡´æ€§ã€‚GPT-5èƒ½å¤Ÿå‡†ç¡®åˆ†ç±»ç—…ä¾‹ï¼Œç”Ÿæˆåˆç†çš„ä¸´åºŠè§£é‡Šï¼Œå¹¶æä¾›æ˜“äºç†è§£çš„æ‚£è€…è¯´æ˜ã€‚è¿™è¡¨æ˜GPT-5æœ‰æ½œåŠ›æˆä¸ºä¸´åºŠåŒ»ç”Ÿå’Œæ‚£è€…çš„åŒé‡ç”¨é€”å·¥å…·ï¼Œæå‡ç³–å°¿ç—…ç®¡ç†çš„æ•ˆç‡å’Œè´¨é‡ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶æˆæœå¯åº”ç”¨äºä¸´åºŠå†³ç­–æ”¯æŒç³»ç»Ÿï¼Œè¾…åŠ©åŒ»ç”Ÿè¿›è¡Œç³–å°¿ç—…æ—©æœŸè¯Šæ–­å’Œé£é™©è¯„ä¼°ã€‚åŒæ—¶ï¼Œç”Ÿæˆçš„æ‚£è€…å‹å¥½è§£é‡Šå¯æé«˜æ‚£è€…å¯¹ç–¾ç—…çš„ç†è§£å’Œæ²»ç–—ä¾ä»æ€§ã€‚æœªæ¥ï¼Œè¯¥æŠ€æœ¯æœ‰æœ›æ‰©å±•åˆ°å…¶ä»–æ…¢æ€§ç–¾ç—…çš„è¯Šæ–­å’Œç®¡ç†ï¼Œå®ç°è¿œç¨‹å¥åº·ç›‘æµ‹å’Œä¸ªæ€§åŒ–æ²»ç–—ã€‚

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> Diabetes mellitus is a major global health challenge, affecting over half a billion adults worldwide with prevalence projected to rise. Although the American Diabetes Association (ADA) provides clear diagnostic thresholds, early recognition remains difficult due to vague symptoms, borderline laboratory values, gestational complexity, and the demands of long-term monitoring. Advances in large language models (LLMs) offer opportunities to enhance decision support through structured, interpretable, and patient-friendly outputs. This study evaluates GPT-5, the latest generative pre-trained transformer, using a simulation framework built entirely on synthetic cases aligned with ADA Standards of Care 2025 and inspired by public datasets including NHANES, Pima Indians, EyePACS, and MIMIC-IV. Five representative scenarios were tested: symptom recognition, laboratory interpretation, gestational diabetes screening, remote monitoring, and multimodal complication detection. For each, GPT-5 classified cases, generated clinical rationales, produced patient explanations, and output structured JSON summaries. Results showed strong alignment with ADA-defined criteria, suggesting GPT-5 may function as a dual-purpose tool for clinicians and patients, while underscoring the importance of reproducible evaluation frameworks for responsibly assessing LLMs in healthcare.

